Franklin Templeton argues that biotechnology is transitioning from a speculative innovation story into a scalable, multi-year growth industry driven by AI, faster approvals, and new treatment platforms.
- Cell and gene therapies are moving toward commercial scale as manufacturing, delivery systems, and clinical validation improve across cancer and rare-disease treatments.
- AI is increasingly embedded throughout drug discovery and development, potentially lowering R&D costs, improving trial success rates, and accelerating commercialization timelines.
- New delivery technologies and expanding use cases for existing drugs — particularly GLP-1 therapies — are broadening addressable markets and supporting longer product cycles.
The report ultimately frames biotech less as a binary clinical-risk sector and more as a compounding innovation ecosystem increasingly shaped by platform economics and AI-driven productivity.
Continue reading this article?
Register for free and get access to Investment Officer International:
- Exclusive for professional investors
- Cancel anytime
- Unlimited access: web, app and newsletters
Registration takes less than 1 minute.
No payment details required
Register for free and get access to Investment Officer Luxembourg:
- Exclusive for professional investors
- Cancel anytime
- Unlimited access: web, app and newsletters
Registration takes less than 1 minute.
No payment details required
